GENSPEED’s groundbreaking combined COVID-19 rapid test

683 1024 EOSS Industries Holding GmbH

Genspeed Biotech is developing the first COVID19 point-of-care assay that allows both infected and recovered patients to be tested in a single run in just minutes.

The development of the test is supported by the Austrian Research Promotion Agency under the COVID-19 Emergency Call. In its final stage, the combined test allows the simultaneous detection of antibodies as well as an acute viral infection in laboratory quality in just a few minutes. This makes the test unique in the world, as it can identify immune or acutely infected individuals for the first time on site, quickly and reliably. The range of applications is broad: whether for testing patients in doctors’ offices, staff and visitors in healthcare facilities or companies, or even travelers at airports.

Cooperation with medical research partners such as the Medical Faculty of the Johannes Kepler University, the Medical University of Graz, the Ludwig Boltzmann Institute and the BOKU in Vienna enable the highest quality in the implementation of the project. In any case, the first COVID-19 measurement results are very promising.

Company contact:
Kerstin Schanda
Corporate Communications
+43 664 819 3022
Wenn Sie unsere Website besuchen, kann sie Informationen über Ihren Browser aus bestimmten Diensten speichern, in der Regel in Form von Cookies. Hier können Sie Ihre Datenschutzeinstellungen ändern. Es ist zu beachten, dass das Blockieren einiger Arten von Cookies Ihre Erfahrungen auf unserer Website und die von uns angebotenen Dienste beeinträchtigen kann.
Click to enable/disable Google Analytics tracking code.
Click to enable/disable Google Fonts.
Click to enable/disable Google Maps.
Click to enable/disable video embeds.
Unsere Website verwendet Cookies, hauptsächlich von Drittanbietern. Definieren Sie Ihre Datenschutzeinstellungen und/oder stimmen Sie der Verwendung von Cookies zu. Besuchen Sie unsere Datenschutz Seite für weitere Informationen.